There are currently 1140 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Let's K-Talk - HPV Study for Ethnic Koreans
NCT05884697
Recruiting
The goal of this clinical trial is to test the feasibility, acceptability, and preliminary efficacy of a storytelling video-based intervention using AI chatbot technology (K-Talk) to promote HPV vaccination behavior among Korean Americans aged 18 to 45. The main questions this study aims to answer are: Is the K-Talk intervention feasible for use among Korean Americans aged 18 to 45? Is the K-Talk intervention acceptable to the target population? What is the preliminary efficacy of the K-Talk i... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
05/29/2024
Locations: Minjin Kim, Cincinnati, Ohio
Conditions: Human Papillomavirus Viruses, Papillomavirus Vaccines
Register for Updates
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
NCT04799054
Recruiting
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Pha... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Ascendis Pharma Investigational Site, Cincinnati, Ohio
Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/29/2024
Locations: Site 202, Cincinnati, Ohio
Conditions: Major Depressive Disorder
Register for Updates
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
All
Ages:
Between 6 months and 30 years
Trial Updated:
05/29/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Mature B-Cell Non-Hodgkin Lymphoma
Register for Updates
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
NCT04763200
Recruiting
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
05/29/2024
Locations: Linder Research Center (The Christ Hospital), Cincinnati, Ohio
Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Good Samaritan Hospital, Cincinnati, Ohio +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
NCT05560646
Recruiting
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
05/29/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Endometriosis
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Parkinson's Disease
Register for Updates
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864
Recruiting
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Research Site, Cincinnati, Ohio +1 locations
Conditions: Breast Cancer
Register for Updates
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
NCT05047172
Recruiting
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Gender:
All
Ages:
30 years and above
Trial Updated:
05/28/2024
Locations: Good Samaritan Hospital, Cincinnati, Ohio +1 locations
Conditions: Intracranial Arteriosclerosis, Stroke
Register for Updates
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. The study will last about 18 months
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Bernstein Clinical Research Center, LLC, Cincinnati, Ohio
Conditions: Perennial Allergic Rhinitis (PAR)
Register for Updates
Histologic Comparison of Ablative Techniques for Endometriosis
NCT06414083
Recruiting
To our knowledge, no other human studies directly compare the effectiveness of the various ablative technologies. We set out to design a study to directly compare ablative energy sources and evaluate their ability to destroy native endometriosis tissue in humans.
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Good Samaritan Hospital, Cincinnati, Ohio
Conditions: Endometriosis, Endometriosis-related Pain, Endometriosis Pelvic, Endometriosis; Peritoneum
Register for Updates